LabGenius Therapeutics

Combining human and machine intelligence to discover the next generation of therapeutic antibodies.

[James Field @jejfield]

Excited to see @nvidia CEO Jensen Huang feature @labgeni_us at the opening of his GTC Paris keynote today! 🤩

Livestream here - 🎥 - https://t.co/0U9uRb1KSY

[Surgery and Cancer @ImperialSandC]

Great to see S&C's own Dr Olivier Pardo talking to @CNN about @labgeni_us working on using #AI to help discover cancer-killing molecules ⬇️

https://t.co/EiBZenJFKc

[LabGenius Therapeutics @labgeni_us]

We’re excited to announce that Dr. Angus Sinclair has joined LabGenius Therapeutics as Chief Scientific Officer (CSO).

Dr. Sinclair will leverage his wealth of drug discovery and development experience to lead LabGenius’ scientific strategy, driving pipeline and platform innovation. He succeeds Dr. Gino Van Heeke, who, following his retirement, will continue to support the company as a Scientific Advisor.

“I’m delighted to welcome Angus to the team,” commented LabGenius CEO Dr. James Field. “He joins us at an exciting time, as our internal programmes continue to generate increasingly compelling data. These results, coupled with Angus’ impressive track record of advancing drug candidates into preclinical and clinical development, will further accelerate the company’s progress. I would also like to express my gratitude to Gino for his unwavering dedication to LabGenius. His expertise and leadership have been instrumental in the discovery and development of the solid tumour-targeting antibodies in our rapidly progressing pipeline.”

Read more about the appointment here: https://t.co/niqzfnQB3M

[LabGenius Therapeutics @labgeni_us]

Attending Bio€quity Europe?

Join our CEO, James Field, for his presentation describing how LabGenius Therapeutics is combining ML with automated functional screening to enable the rapid discovery of complex multispecifics, like T-cell engagers.

In this talk, James will explain how our closed-loop antibody discovery platform, EVA™, can unlock high-performing, often non-intuitive molecular designs. These ‘smart’ antibodies overcome common challenges associated with tumour-targeting antibodies, including on-target, off-tumour toxicity.

To learn more about LabGenius’ cutting-edge platform and therapeutic pipeline email us at [email protected].

[James Field @jejfield]

🎥 Delighted to see @labgeni_us featured on @CNN's Blueprint series.

In the episode, we share how we've integrated high-throughput experimentation with machine learning to discover safer, more effective cancer therapies.

[LabGenius Therapeutics @labgeni_us]

🎥 LabGenius Therapeutics was recently featured on @CNN's Blueprint series.

In the episode, we share how our expert team of scientists and engineers have built a cutting-edge, highly automated platform that integrates high-throughput experimentation with machine learning to discover safer, more effective antibody therapies.

The feature gives a behind-the-scenes look at our recent platform expansion, designed to increase experimental throughput and generate more high-quality characterisation data — further strengthening our ML-enabled discovery process.

Watch the video here: https://t.co/QgeiyxHkSL

[BioSpace @biospace]

AI is enabling the development of a next generation of drugs that can more precisely target cancer cells while sparing healthy tissues.

#AI #cancertreatment #biospace
https://t.co/3kc7gSUhhZ

[LabGenius Therapeutics @labgeni_us]

LabGenius’ CSO, Gino Van Heeke, recently wrote an article for @biospace, exploring how the next generation of ‘smart’ antibodies will transform the fight against solid tumours.

The piece delves into a critical challenge: overcoming on-target, off-tumour toxicity—a key obstacle in developing safer and more effective antitumor therapies.

He explains that while conventional approaches to enhancing selectivity may result in incremental gains, we should be aiming for complete on/off killing selectivity.

Addressing this challenge would not only reduce the toxicity burden too often associated with antitumour therapies but it would also expand the pool of viable targets.

🔗 Read the full article here: https://t.co/ec98qCTeK6

[LabGenius Therapeutics @labgeni_us]

Thank you @NewsMedical for a brilliant interview with Mohammed Akhlaq, Head of Automation at LabGenius Therapeutics. In this interview, Mohammed explains the importance of our recent platform expansion.

“It's the high-quality, disease-relevant data generated by our platform that fuels our active learning process. The more experimental data we produce, the stronger our ML-enabled antibody discovery process becomes.”

🔗 Read the full interview here: https://t.co/QqyXpQ5wgI

[LabGenius Therapeutics @labgeni_us]

Attending BioTrinity (@OBN_UK) next week?

Join @labgeni_us' CEO, James Field, for his Science Spotlight presentation describing how our unique discovery platform is being used to establish a wholly-owned pipeline of highly selective T-cell engagers for the treatment of solid tumours.

LabGenius’ platform, which is underpinned by the closed-loop integration of ML and high-throughput experimentation, enables the rapid identification and co-optimisation of complex multispecific antibodies across multiple key properties, including killing selectivity, potency and developability.

Find the full conference agenda here: https://t.co/9tjA8Mugqp

To learn more about LabGenius’ cutting-edge platform and therapeutic pipeline, please email us at [email protected]

[LabGenius Therapeutics @labgeni_us]

We’re excited to announce that Dr. Hannah Seitz has joined the LabGenius Team as Chief Business Officer.

Hannah, who was previously Evotec’s VP Global Business Development, will lead LabGenius’ business development activities.

“We’re delighted that Hannah has joined the team,” said Dr. James Field, CEO of LabGenius. “Her extensive experience in sourcing and executing deals, combined with our proven ability to discover high-performing molecules with non-intuitive designs, will be instrumental in the success of our partnerships.”

Read more about the appointment here: https://t.co/utiLrq7VGS

[LabGenius Therapeutics @labgeni_us]

Attending The BioLogic Summit next week?

Join our Head of Data Science and Machine Learning, Dr. Winston Haynes, for his presentation describing how LabGenius’ unique discovery platform is being used to establish a wholly-owned pipeline of highly selective T-cell engagers for the treatment of solid tumours.

LabGenius’ platform, which is underpinned by the closed-loop integration of ML and high-throughput experimentation, is enabling the company to pursue targets that have traditionally been associated with on-target, off-tumour toxicity.

Find out more here: https://t.co/wevBL1W5oR

[LabGenius Therapeutics @labgeni_us]

Did you miss our presentation at #PEGSEurope?

Watch the video below to hear James Field describe how LabGenius' unique discovery platform is being used to establish a wholly-owned pipeline of highly selective T-cell engagers for the treatment of solid tumours. LabGenius’ platform, which is underpinned by the closed-loop integration of ML and high-throughput experimentation, is enabling the company to pursue targets that have traditionally been associated with on-target off-tumour toxicity.

Interested in learning more? Get in touch via: [email protected]

[LabGenius Therapeutics @labgeni_us]

Are you attending #PEGSEurope?

Join our CEO, James Field, as he describes how LabGenius’ unique discovery platform is being used to establish a wholly-owned pipeline of highly selective T-cell engagers for the treatment of solid tumours. LabGenius’ platform, which is underpinned by the closed-loop integration of ML and high-throughput experimentation, is enabling the company to pursue targets that have traditionally been associated with on-target off-tumour toxicity.

📅 Wednesday, 6 November 2024
⏰ 12:15 pm
📍#PEGSEurope, Spain

[SynbiCITE @SynbiCITE]

We're pleased to announce that James Field, CEO of LabGenius will be speaking at SynbiTECH 2024!

Secure your ticket now: https://t.co/gbl2mEAiKs

#SynbiTECH24 #SynBio #SyntheticBiology

[MC HAMMER e/acc @MCHammer]

Congratulations @jejfield and the @labgeni_us team !!! Accelerate 🚀🚀🚀
London to the Bay !!! #Hamm400✨✍🏽

[LabGenius Therapeutics @labgeni_us]

EXCITING NEWS! 📣 Today we announce LabGenius’ £35 million Series B fundraise! 🎉🚀

With these funds, we’ll be accelerating the development of both our ML-driven drug discovery platform and therapeutic pipeline of multispecific antibodies 🔬

🗞️ For more details on the round, check out the press release here - https://t.co/srm0gRAfxn

💡Our CEO, @jejfield, shares his personal perspective on what this financing means for LabGenius here - https://t.co/HSxuDBlMwQ

[LabGenius Therapeutics @labgeni_us]

Great to talk today at the @PEGSboston summit! 👏 @hayneswa

[MC HAMMER e/acc @MCHammer]

#Hamm400aos @labgeni_us
Change and Save lives. ✨✨✨